KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Gains from Sales and Divestitures (2016 - 2021)

Historic Gains from Sales and Divestitures for Resmed (RMD) over the last 9 years, with Q2 2021 value amounting to $704000.0.

  • Resmed's Gains from Sales and Divestitures fell 2421.96% to $704000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $704000.0, marking a year-over-year decrease of 2421.96%. This contributed to the annual value of $704000.0 for FY2021, which is 2421.96% down from last year.
  • As of Q2 2021, Resmed's Gains from Sales and Divestitures stood at $704000.0, which was down 2421.96% from $929000.0 recorded in Q2 2020.
  • Resmed's Gains from Sales and Divestitures' 5-year high stood at $929000.0 during Q2 2020, with a 5-year trough of $2911.0 in Q3 2018.
  • For the 5-year period, Resmed's Gains from Sales and Divestitures averaged around $548938.5, with its median value being $624617.0 (2017).
  • Per our database at Business Quant, Resmed's Gains from Sales and Divestitures crashed by 6855.73% in 2017 and then skyrocketed by 7815.18% in 2019.
  • Over the past 5 years, Resmed's Gains from Sales and Divestitures (Quarter) stood at $624617.0 in 2017, then surged by 41.95% to $886655.0 in 2018, then fell by 2.86% to $861256.0 in 2019, then grew by 7.87% to $929000.0 in 2020, then decreased by 24.22% to $704000.0 in 2021.
  • Its last three reported values are $704000.0 in Q2 2021, $929000.0 for Q2 2020, and $915450.0 during Q1 2020.